Silvetti Massimo Stefano, Drago Fabrizio, Grutter Giorgia, De Santis Antonella, Di Ciommo Vincenzo, Ravà Lucilla
Aritmologia, Dipartimento Medico-Chirurgico di Cardiologia Pediatrica, Ospedale Pediatrico Bambino Gesù, Piazza S. Onofrio 4, 00165 Roma, Italia.
Europace. 2006 Jul;8(7):530-6. doi: 10.1093/europace/eul062.
The aim of this study was to evaluate long-term outcome of pacemakers (PMs) in paediatric patients.
Patients' data were retrospectively reviewed. We recorded the techniques and systems used, any complication, and outcome. Endocardial leads were inserted by transcutaneous puncture of subclavian vein and fixed with a non-absorbable ligature, and epicardial leads by standard surgical technique. Lead survival was calculated and plotted with the product limit method of Kaplan-Meier. Between 1982 and 2002, 292 patients, aged 8+/-7 years (range 1 day-18 years), underwent PM implantation: the first PM had endocardial leads in 165 patients and epicardial in 127 patients. Structural heart disease (HD) was present in 239 patients. Follow-up was 5+/-4 (range 0.1-18) years. There were no pacing-related deaths. In total, 211 endocardial implantation procedures with 90 atrial and 165 ventricular leads and 145 epicardial procedures with 103 atrial and 123 ventricular leads were performed. Early (<3 months) complications: haemothorax occurred in 3.5% of endocardial leads and dislodgement was not significantly different for atrial and ventricular endocardial leads. Late complications: 63 leads failed (48 epicardial), with the worst outcome for conventional epicardial leads (31 vs. 9% endocardial, P<0.05; steroid eluting 8% epicardial vs. 5% endocardial, P=NS). Endocardial atrial leads failed (7%) in operated HD and ventricular leads failed (6%) after body growth, without difference in estimated mean survival time (11 years). Early and late PM infection/erosion was approximately 2% in all patients.
Pacing in children shows good results, but complications are frequent and related to leads. Endocardial pacing showed better long-term outcome.
本研究旨在评估儿科患者起搏器(PM)的长期疗效。
对患者数据进行回顾性分析。记录所使用的技术和系统、任何并发症及疗效。经皮穿刺锁骨下静脉插入心内膜导线,并用不可吸收结扎线固定,采用标准外科技术植入心外膜导线。计算导线生存率,并用Kaplan-Meier乘积限法绘制生存曲线。1982年至2002年期间,292例年龄为8±7岁(范围1天至18岁)的患者接受了PM植入:首次植入PM时,165例患者采用心内膜导线,127例患者采用心外膜导线。239例患者存在结构性心脏病(HD)。随访时间为5±4年(范围0.1至18年)。无起搏相关死亡。共进行了211例心内膜植入手术,包括90根心房导线和165根心室导线,以及145例心外膜手术,包括103根心房导线和123根心室导线。早期(<3个月)并发症:3.5%的心内膜导线出现血胸,心房和心室心内膜导线的移位无显著差异。晚期并发症:63根导线发生故障(48根心外膜导线),传统心外膜导线的预后最差(心外膜导线为31%,心内膜导线为9%,P<0.05;类固醇洗脱心外膜导线为8%,心内膜导线为5%,P=无显著性差异)。在接受手术的HD患者中,心内膜心房导线故障率为7%,身体生长后心室导线故障率为6%,估计平均生存时间无差异(11年)。所有患者的早期和晚期PM感染/侵蚀率约为2%。
儿童起搏显示出良好的效果,但并发症频繁且与导线有关。心内膜起搏显示出更好的长期疗效。